[go: up one dir, main page]

DK1260521T3 - Immunoglobulinvarianter af specifikke Fc-epsilonreceptorer - Google Patents

Immunoglobulinvarianter af specifikke Fc-epsilonreceptorer

Info

Publication number
DK1260521T3
DK1260521T3 DK02009009T DK02009009T DK1260521T3 DK 1260521 T3 DK1260521 T3 DK 1260521T3 DK 02009009 T DK02009009 T DK 02009009T DK 02009009 T DK02009009 T DK 02009009T DK 1260521 T3 DK1260521 T3 DK 1260521T3
Authority
DK
Denmark
Prior art keywords
ige
receptor
specific
binding
useful
Prior art date
Application number
DK02009009T
Other languages
English (en)
Inventor
Paula M Jardieu
Leonard G Presta
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27114350&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1260521(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1260521T3 publication Critical patent/DK1260521T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK02009009T 1991-08-14 1992-08-14 Immunoglobulinvarianter af specifikke Fc-epsilonreceptorer DK1260521T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74476891A 1991-08-14 1991-08-14
US87949592A 1992-05-07 1992-05-07
PCT/US1992/006860 WO1993004173A1 (en) 1991-08-14 1992-08-14 Immunoglobulin variants for specific fc epsilon receptors

Publications (1)

Publication Number Publication Date
DK1260521T3 true DK1260521T3 (da) 2008-03-25

Family

ID=27114350

Family Applications (2)

Application Number Title Priority Date Filing Date
DK92918713T DK0602126T3 (da) 1991-08-14 1992-08-14 Immunoglobulinvarianter til specifikke FC epsilon-receptorer
DK02009009T DK1260521T3 (da) 1991-08-14 1992-08-14 Immunoglobulinvarianter af specifikke Fc-epsilonreceptorer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK92918713T DK0602126T3 (da) 1991-08-14 1992-08-14 Immunoglobulinvarianter til specifikke FC epsilon-receptorer

Country Status (11)

Country Link
EP (2) EP1260521B1 (da)
JP (1) JP3457962B2 (da)
AT (1) ATE233813T1 (da)
AU (2) AU2498192A (da)
CA (1) CA2113813C (da)
DE (3) DE69233716T2 (da)
DK (2) DK0602126T3 (da)
ES (2) ES2296839T3 (da)
LU (1) LU91219I2 (da)
NL (1) NL300220I2 (da)
WO (1) WO1993004173A1 (da)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770396A (en) * 1992-04-16 1998-06-23 The United States Of America As Represented By The Department Of Health And Human Services Isolation characterization, and use of the human beta subunit of the high affinity receptor for immunoglobulin E
ATE264388T1 (de) * 1992-09-24 2004-04-15 Tanox Biosystems Inc Umgestaltete monoklonale antikörper gegen ein immunglobulinisotyp
US5958708A (en) * 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6066718A (en) * 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5928904A (en) * 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
GB9324013D0 (en) * 1993-11-22 1994-01-12 3I Res Expl Ltd Polypeptides
AP660A (en) * 1994-01-18 1998-08-18 Genentech Inc A method of treatment of parasitic infection using IgE antagonists.
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US20040197326A1 (en) * 1995-07-27 2004-10-07 Genentech, Inc. Method for treatment of allergic asthma
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CN1174998C (zh) * 1996-03-01 2004-11-10 诺瓦提斯公司 用于预防和治疗过敏的肽免疫原
US5958880A (en) * 1996-12-19 1999-09-28 Heska Corporation Feline Fc epsilon receptor alpha chain proteins and therapeutic uses thereof
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6057127A (en) * 1998-01-29 2000-05-02 Heska Corporation Equine Fc epsilon receptor alpha chain nucleic acid molecules and uses thereof
US6504013B1 (en) * 2000-02-01 2003-01-07 Idexx Laboratories, Inc. Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody
US7393529B2 (en) * 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6299875B1 (en) * 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
TR200102493T2 (tr) * 1999-02-25 2002-02-21 Smithkline Beecham Biologicals S.A. IgE'nin C-epsilon-3 veya C-epsilon-4 alanlarından türetilmiş epitoplar veya mimotoplar.
US6889145B1 (en) 2000-03-15 2005-05-03 Northwestern University Three-dimensional model of a Fc region of an IgE antibody and uses thereof
CA2423227C (en) 2000-10-12 2011-11-29 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
WO2003066662A2 (en) 2002-02-05 2003-08-14 Genentech, Inc. Protein purification
DK1501369T3 (da) 2002-04-26 2015-09-28 Genentech Inc Ikke-affinitetsoprensning af proteiner
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
AU2003283137B8 (en) 2002-11-08 2010-07-29 Ablynx N.V. Camelidae antibodies against immunoglobulin E and use thereof for the treatment of allergic disorders
EP2284192A3 (en) 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
SI2335725T1 (sl) 2003-04-04 2017-01-31 Genentech, Inc. Visokokoncentrirane formulacije protiteles in proteinov
LT3095793T (lt) 2003-07-28 2020-07-10 Genentech, Inc. Baltymo a išplovimo sumažinimas afininės baltymo a chromatografijos metu
JP2007531707A (ja) 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
TWI391399B (zh) 2005-05-25 2013-04-01 Hoffmann La Roche 測定溶離多肽之鹽濃度之方法
WO2007032804A2 (en) 2005-06-30 2007-03-22 Clifford Risk Novel uses for anti-ige therapy
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
WO2008079280A1 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
ES2426158T3 (es) 2007-01-22 2013-10-21 Genentech, Inc. Precipitación con polielectrolito y purificación de anticuerpos
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
EP2188302B1 (en) 2007-07-09 2017-11-01 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
PE20090499A1 (es) 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37
EP2184608B1 (en) * 2007-08-23 2016-10-05 LSI Medience Corporation Non-specific reaction inhibitor
PL2840090T3 (pl) 2007-10-30 2018-07-31 Genentech, Inc. Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
PT3604324T (pt) 2008-08-14 2024-05-10 Genentech Inc Métodos para remover um contaminante com a utilização de cromatografia de membrana de permuta iónica de deslocação de proteína indígena
EP2334323A2 (en) 2008-09-10 2011-06-22 F. Hoffmann-La Roche AG Compositions and methods for the prevention of oxidative degradation of proteins
JP2012512244A (ja) 2008-12-16 2012-05-31 イー・エム・デイー・ミリポア・コーポレイシヨン タンパク質の精製
EP2370561B1 (en) 2008-12-16 2019-08-07 EMD Millipore Corporation Stirred tank reactor and method
WO2010099273A1 (en) 2009-02-27 2010-09-02 Genentech, Inc. Methods and compositions for protein labelling
PE20120359A1 (es) 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
MX355650B (es) 2009-08-11 2018-04-26 Genentech Inc Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
US9428548B2 (en) 2009-09-01 2016-08-30 Genentech, Inc. Enhanced protein purification through a modified protein A elution
JP5937059B2 (ja) 2010-03-22 2016-06-22 ジェネンテック， インコーポレイテッド タンパク質含有製剤の安定化に有用な組成物及び方法
MX2012012743A (es) 2010-05-03 2012-11-23 Genentech Inc Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
KR101551295B1 (ko) 2010-05-17 2015-09-08 이엠디 밀리포어 코포레이션 생체분자 정제용 자극 반응성 중합체
WO2011150241A2 (en) 2010-05-28 2011-12-01 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
MY184736A (en) 2010-06-24 2021-04-20 Genentech Inc Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
BR112013003279A2 (pt) 2010-08-13 2016-06-14 Genentech In “métodos para tratar uma doença, método para neutralizar ou bloquear a atividade de il-1ß e/ou il-18, anticorpo, usos de um anticorpo e usos de um anticorpo monoclonal”
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
KR101949187B1 (ko) 2011-07-08 2019-04-22 이엠디 밀리포어 코포레이션 일회용 생명공학적 공정용의 개선된 심층 필터
EP2791172B1 (en) 2011-12-16 2017-07-19 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
RU2648999C2 (ru) 2011-12-22 2018-03-29 Дженентек, Инк. Способы повышения эффективности этапов очистки белка, находящихся ниже по потоку, с использованием мембранной ионообменной хроматографии
CA2866753C (en) 2012-03-27 2020-09-22 Genentech, Inc. Improved harvest operations for recombinant proteins
ES2682761T3 (es) 2012-05-18 2018-09-21 Genentech, Inc. Formulaciones de anticuerpos monoclonales de alta concentración
GB2503883A (en) * 2012-07-09 2014-01-15 King S College London Variant IgE with reduced affinity to CD23
CN104994885B (zh) 2012-12-19 2017-09-29 基因泰克公司 用于放射性卤素蛋白质标记的方法和组合物
HRP20201663T1 (hr) 2014-07-09 2020-12-25 F. Hoffmann - La Roche Ag PRILAGOĐAVANJE pH VRIJEDNOSTI RADI POBOLJŠANJA OPORAVKA BANAKA STANICA USLIJED ODMRZAVANJA
JP2019510517A (ja) 2016-03-29 2019-04-18 ジェルター， インコーポレイテッド 細胞質内体積に対するペリプラズム体積の比率が０．５：１および１０：１の間にあるグラム陰性細菌におけるタンパク質の発現
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
WO2018119312A1 (en) 2016-12-22 2018-06-28 Genentech, Inc. Methods and formulations for reducing reconstitution time of lyophilized polypeptides
JP7128191B2 (ja) * 2017-01-06 2022-08-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 治療抗ＩｇＥ抗体並びにその方法及び組成物
EP3635093A1 (en) 2017-06-08 2020-04-15 Polpharma Biologics S.A. Improved methods of cell culture
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
RU2020113059A (ru) 2017-11-07 2021-12-08 Хьюбит Дженомикс,Инк. Способ первичного предотвращения аллергических заболеваний у детей младенческого возраста с помощью специфичной иммуносупрессии иммуноглобулинов класса ige
LT3818078T (lt) 2018-07-03 2024-04-25 Bristol-Myers Squibb Company Rekombinantinių baltymų gamybos būdas
KR20210074341A (ko) 2018-10-10 2021-06-21 베링거 인겔하임 인터내셔날 게엠베하 고밀도 생물 반응기 배양에서 막 기체 전달을 위한 방법
TWI856084B (zh) 2019-04-01 2024-09-21 美商建南德克公司 用於穩定含有蛋白質之配方之組合物及方法
JP7777451B2 (ja) 2019-04-12 2025-11-28 ジェルター， インコーポレイテッド 組換えエラスチンおよびその産生
CN114514311A (zh) 2019-08-01 2022-05-17 百时美施贵宝公司 改进补料分批细胞培养物中蛋白质产量的方法
CN115175736A (zh) * 2019-10-01 2022-10-11 艾普西洛根有限公司 杂交抗体
JP2023541217A (ja) 2020-07-10 2023-09-29 シャンハイ ジェミンケア ファーマシューティカル カンパニー，リミティド 抗ＩｇＥ改変抗体及びその適用
CN116194570A (zh) 2020-09-22 2023-05-30 百时美施贵宝公司 用于产生治疗性蛋白的方法
US20250115666A1 (en) 2021-08-05 2025-04-10 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
WO2023049687A1 (en) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
US12509529B2 (en) 2024-05-17 2025-12-30 Excellergy, Inc. Antibodies and antibody fragments that bind IgE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954617A (en) * 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
JPS63225397A (ja) * 1986-10-03 1988-09-20 Dainippon Pharmaceut Co Ltd 抗アレルギー作用を有する新規ペプチド
US4940782A (en) * 1987-06-08 1990-07-10 G. D. Searle & Co. Monoclonal antibodies against IgE-associated determinants, hybrid cell lines producing these antibodies, and use therefore
GB8727045D0 (en) * 1987-11-19 1987-12-23 Research Corp Ltd Immunoglobulin e competitor
AU618317B2 (en) * 1987-12-31 1991-12-19 Tanox Biosystems, Inc. Unique antigenic epitopes on ige-bearing b lymphocytes

Also Published As

Publication number Publication date
ES2193136T3 (es) 2003-11-01
HK1050696A1 (en) 2003-07-04
ES2296839T3 (es) 2008-05-01
DE69232944T2 (de) 2003-12-24
ATE233813T1 (de) 2003-03-15
AU2498192A (en) 1993-03-16
DK0602126T3 (da) 2003-06-16
LU91219I2 (fr) 2006-04-03
JPH06509944A (ja) 1994-11-10
NL300220I2 (nl) 2006-08-01
AU706584C (en) 2003-07-10
WO1993004173A1 (en) 1993-03-04
DE69232944D1 (de) 2003-04-10
EP1260521B1 (en) 2007-11-21
EP1260521A2 (en) 2002-11-27
AU706584B2 (en) 1999-06-17
NL300220I1 (nl) 2006-04-03
JP3457962B2 (ja) 2003-10-20
CA2113813A1 (en) 1993-03-04
HK1014542A1 (en) 1999-09-30
DE122006000006I2 (de) 2011-06-16
DE122006000006I1 (de) 2006-04-27
EP0602126B1 (en) 2003-03-05
AU7038096A (en) 1997-01-16
DE69233716D1 (de) 2008-01-03
CA2113813C (en) 2005-04-12
EP0602126A1 (en) 1994-06-22
EP1260521A3 (en) 2004-01-02
DE69233716T2 (de) 2008-10-30

Similar Documents

Publication Publication Date Title
DK1260521T3 (da) Immunoglobulinvarianter af specifikke Fc-epsilonreceptorer
ATE443139T1 (de) Menschliche toll-ähliche rezeptorproteine, zugehörige reagenzien und verfahren
ATE197053T1 (de) Humaner rezeptor fc(gamma)riii
PT842273E (pt) Ligando de receptor vegf-c
DK1157042T3 (da) Fremstilling af tetravalente antistoffer
ES2187946T3 (es) Uso de interleucina-15.
DE3750342D1 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
ATE317852T1 (de) Pollen allergene
DE68925226D1 (de) Monoklonale Antikörper
DK0491362T3 (da) Anvendelse af peptidpar med ekstremt høj indbyrdesaffinitet på in vitro - diagnostikområdet
PT954333E (pt) Receptores soluveis de linfotoxina-beta, anticorpos de receptores de anti-linfotoxina e anticorpos de ligandos de anti-linfotoxina como agentes terapeuticos para o tratamento de doencas imunologicas
WO1999046379A3 (en) Human receptor proteins; related reagents and methods
DE69233673D1 (de) Protein S polypeptide und deren Verwendungen
DE69232975D1 (de) Protein p100von menschlichem Herpesvirus Typ 6, die korrespondierenden DNS Squenzen, ihre Herstellung und Verwendung
EP0651800A4 (en) PROTEINS ENCOUNTERED IN BASOPHILIC GRANULATIONS.
ATE193021T1 (de) Lipoprotein (a)-peptide und deren verwendung